ImmunityBio, Inc.'s Anktiva shows promise for solid tumors, with growing sales and financing boosting growth potential. Click ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the unique, permanent Healthcare Common ...

ImmunityBio IBRX shares rallied 27.2% on Thursday after it announced that it has completed the regulatory filing process in ...

ImmunityBio is at the forefront of developing innovative immunotherapies and cell therapies. The company has a vertically integrated approach, allowing it to oversee every step of development, from ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced significant progress in its ongoing ...

Shares in ImmunityBio were in freefall today after it revealed the FDA had rejected its marketing application for Anktiva as a treatment for bladder cancer. In a complete response letter (CRL ...

CG Oncology's stock has dropped 40% since its IPO peak, driven by profit-taking and competitive concerns despite promising ...

Shares of ImmunityBio (NASDAQ:IBRX) were up 15% in midday trading Thursday, the day after it issued updates on its regulatory ...

BTIG analyst Justin Zelin initiated coverage of ImmunityBio (IBRX) with a Buy rating and $6 price target Lead product Anktiva is approved in ...

The company plans to use the net proceeds from this offering to advance the commercialization of ANKTIVA for treating certain types of bladder cancer, fund trials for bladder cancer and non-small ...

CULVER CITY, Calif. - ImmunityBio, Inc. (NASDAQ:IBRX), a biotechnology firm, has announced the assignment of a unique permanent J-code for ANKTIVA (nogapendekin alfa inbakicept-pmln) by the ...

The U.S. Food and Drug Administration (FDA) approved ANKTIVA with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer ...